Market Overview
The global Oncolytic Virus Cancer Immunotherapy market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.
The Oncolytic Virus Cancer Immunotherapy market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
Market segmentation
Oncolytic Virus Cancer Immunotherapy market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
By Type, Oncolytic Virus Cancer Immunotherapy market has been segmented into:
Monoclonal Antibodies
Checkpoint Inhibitors
Oncoloytic Viral Therapies and Cancer Vaccines
By Application, Oncolytic Virus Cancer Immunotherapy has been segmented into:
Lung Cancer
Breast Cancer
Colorectal Cancer
Melanoma
Prostate Cancer
Head and neck Cancer
Ovarian Cancer
Pancreatic Cancer
Others
Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Oncolytic Virus Cancer Immunotherapy market presented in the report. This section sheds light on the sales growth of different regional and country-level Oncolytic Virus Cancer Immunotherapy markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Oncolytic Virus Cancer Immunotherapy market.
The report offers in-depth assessment of the growth and other aspects of the Oncolytic Virus Cancer Immunotherapy market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Competitive Landscape and Oncolytic Virus Cancer Immunotherapy Market Share Analysis
Oncolytic Virus Cancer Immunotherapy competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Oncolytic Virus Cancer Immunotherapy sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Oncolytic Virus Cancer Immunotherapy sales, revenue and market share for each player covered in this report.
The major players covered in Oncolytic Virus Cancer Immunotherapy are:
AstraZeneca
Biovex
Bristol-Myers Squibb
Amgen
Pfizer
F Hoffman-La Roche
Crusade Laboratories
Merck & Co., Inc.
Novartis AG
Cell Genesys
Genelux Corporation
Lokon Pharma
MultiVir
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Oncolytic Virus Cancer Immunotherapy Market Overview
1.1 Product Overview and Scope of Oncolytic Virus Cancer Immunotherapy
1.2 Classification of Oncolytic Virus Cancer Immunotherapy by Type
1.2.1 Global Oncolytic Virus Cancer Immunotherapy Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global Oncolytic Virus Cancer Immunotherapy Revenue Market Share by Type in 2019
1.2.3 Monoclonal Antibodies
1.2.4 Checkpoint Inhibitors
1.2.5 Oncoloytic Viral Therapies and Cancer Vaccines
1.3 Global Oncolytic Virus Cancer Immunotherapy Market by Application
1.3.1 Overview: Global Oncolytic Virus Cancer Immunotherapy Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Lung Cancer
1.3.3 Breast Cancer
1.3.4 Colorectal Cancer
1.3.5 Melanoma
1.3.6 Prostate Cancer
1.3.7 Head and neck Cancer
1.3.8 Ovarian Cancer
1.3.9 Pancreatic Cancer
1.3.10 Others
1.4 Global Oncolytic Virus Cancer Immunotherapy Market by Regions
1.4.1 Global Oncolytic Virus Cancer Immunotherapy Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of Oncolytic Virus Cancer Immunotherapy (2015-2025)
1.4.3 North America (USA, Canada and Mexico) Oncolytic Virus Cancer Immunotherapy Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) Oncolytic Virus Cancer Immunotherapy Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Oncolytic Virus Cancer Immunotherapy Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) Oncolytic Virus Cancer Immunotherapy Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Oncolytic Virus Cancer Immunotherapy Status and Prospect (2015-2025)
2 Company Profiles
2.1 AstraZeneca
2.1.1 AstraZeneca Details
2.1.2 AstraZeneca Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 AstraZeneca SWOT Analysis
2.1.4 AstraZeneca Product and Services
2.1.5 AstraZeneca Oncolytic Virus Cancer Immunotherapy Revenue, Gross Margin and Market Share (2018-2019)
2.2 Biovex
2.2.1 Biovex Details
2.2.2 Biovex Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Biovex SWOT Analysis
2.2.4 Biovex Product and Services
2.2.5 Biovex Oncolytic Virus Cancer Immunotherapy Revenue, Gross Margin and Market Share (2018-2019)
2.3 Bristol-Myers Squibb
2.3.1 Bristol-Myers Squibb Details
2.3.2 Bristol-Myers Squibb Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Bristol-Myers Squibb SWOT Analysis
2.3.4 Bristol-Myers Squibb Product and Services
2.3.5 Bristol-Myers Squibb Oncolytic Virus Cancer Immunotherapy Revenue, Gross Margin and Market Share (2018-2019)
2.4 Amgen
2.4.1 Amgen Details
2.4.2 Amgen Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Amgen SWOT Analysis
2.4.4 Amgen Product and Services
2.4.5 Amgen Oncolytic Virus Cancer Immunotherapy Revenue, Gross Margin and Market Share (2018-2019)
2.5 Pfizer
2.5.1 Pfizer Details
2.5.2 Pfizer Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Pfizer SWOT Analysis
2.5.4 Pfizer Product and Services
2.5.5 Pfizer Oncolytic Virus Cancer Immunotherapy Revenue, Gross Margin and Market Share (2018-2019)
2.6 F Hoffman-La Roche
2.6.1 F Hoffman-La Roche Details
2.6.2 F Hoffman-La Roche Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 F Hoffman-La Roche SWOT Analysis
2.6.4 F Hoffman-La Roche Product and Services
2.6.5 F Hoffman-La Roche Oncolytic Virus Cancer Immunotherapy Revenue, Gross Margin and Market Share (2018-2019)
2.7 Crusade Laboratories
2.7.1 Crusade Laboratories Details
2.7.2 Crusade Laboratories Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 Crusade Laboratories SWOT Analysis
2.7.4 Crusade Laboratories Product and Services
2.7.5 Crusade Laboratories Oncolytic Virus Cancer Immunotherapy Revenue, Gross Margin and Market Share (2018-2019)
2.8 Merck & Co., Inc.
2.8.1 Merck & Co., Inc. Details
2.8.2 Merck & Co., Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 Merck & Co., Inc. SWOT Analysis
2.8.4 Merck & Co., Inc. Product and Services
2.8.5 Merck & Co., Inc. Oncolytic Virus Cancer Immunotherapy Revenue, Gross Margin and Market Share (2018-2019)
2.9 Novartis AG
2.9.1 Novartis AG Details
2.9.2 Novartis AG Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 Novartis AG SWOT Analysis
2.9.4 Novartis AG Product and Services
2.9.5 Novartis AG Oncolytic Virus Cancer Immunotherapy Revenue, Gross Margin and Market Share (2018-2019)
2.10 Cell Genesys
2.10.1 Cell Genesys Details
2.10.2 Cell Genesys Major Business and Total Revenue (Financial Highlights) Analysis
2.10.3 Cell Genesys SWOT Analysis
2.10.4 Cell Genesys Product and Services
2.10.5 Cell Genesys Oncolytic Virus Cancer Immunotherapy Revenue, Gross Margin and Market Share (2018-2019)
2.11 Genelux Corporation
2.11.1 Genelux Corporation Details
2.11.2 Genelux Corporation Major Business and Total Revenue (Financial Highlights) Analysis
2.11.3 Genelux Corporation SWOT Analysis
2.11.4 Genelux Corporation Product and Services
2.11.5 Genelux Corporation Oncolytic Virus Cancer Immunotherapy Revenue, Gross Margin and Market Share (2018-2019)
2.12 Lokon Pharma
2.12.1 Lokon Pharma Details
2.12.2 Lokon Pharma Major Business and Total Revenue (Financial Highlights) Analysis
2.12.3 Lokon Pharma SWOT Analysis
2.12.4 Lokon Pharma Product and Services
2.12.5 Lokon Pharma Oncolytic Virus Cancer Immunotherapy Revenue, Gross Margin and Market Share (2018-2019)
2.13 MultiVir
2.13.1 MultiVir Details
2.13.2 MultiVir Major Business and Total Revenue (Financial Highlights) Analysis
2.13.3 MultiVir SWOT Analysis
2.13.4 MultiVir Product and Services
2.13.5 MultiVir Oncolytic Virus Cancer Immunotherapy Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global Oncolytic Virus Cancer Immunotherapy Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 Oncolytic Virus Cancer Immunotherapy Players Market Share
3.2.2 Top 10 Oncolytic Virus Cancer Immunotherapy Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global Oncolytic Virus Cancer Immunotherapy Revenue and Market Share by Regions
4.2 North America Oncolytic Virus Cancer Immunotherapy Revenue and Growth Rate (2015-2020)
4.3 Europe Oncolytic Virus Cancer Immunotherapy Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific Oncolytic Virus Cancer Immunotherapy Revenue and Growth Rate (2015-2020)
4.5 South America Oncolytic Virus Cancer Immunotherapy Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa Oncolytic Virus Cancer Immunotherapy Revenue and Growth Rate (2015-2020)
5 North America Oncolytic Virus Cancer Immunotherapy Revenue by Countries
5.1 North America Oncolytic Virus Cancer Immunotherapy Revenue by Countries (2015-2020)
5.2 USA Oncolytic Virus Cancer Immunotherapy Revenue and Growth Rate (2015-2020)
5.3 Canada Oncolytic Virus Cancer Immunotherapy Revenue and Growth Rate (2015-2020)
5.4 Mexico Oncolytic Virus Cancer Immunotherapy Revenue and Growth Rate (2015-2020)
6 Europe Oncolytic Virus Cancer Immunotherapy Revenue by Countries
6.1 Europe Oncolytic Virus Cancer Immunotherapy Revenue by Countries (2015-2020)
6.2 Germany Oncolytic Virus Cancer Immunotherapy Revenue and Growth Rate (2015-2020)
6.3 UK Oncolytic Virus Cancer Immunotherapy Revenue and Growth Rate (2015-2020)
6.4 France Oncolytic Virus Cancer Immunotherapy Revenue and Growth Rate (2015-2020)
6.5 Russia Oncolytic Virus Cancer Immunotherapy Revenue and Growth Rate (2015-2020)
6.6 Italy Oncolytic Virus Cancer Immunotherapy Revenue and Growth Rate (2015-2020)
7 Asia-Pacific Oncolytic Virus Cancer Immunotherapy Revenue by Countries
7.1 Asia-Pacific Oncolytic Virus Cancer Immunotherapy Revenue by Countries (2015-2020)
7.2 China Oncolytic Virus Cancer Immunotherapy Revenue and Growth Rate (2015-2020)
7.3 Japan Oncolytic Virus Cancer Immunotherapy Revenue and Growth Rate (2015-2020)
7.4 Korea Oncolytic Virus Cancer Immunotherapy Revenue and Growth Rate (2015-2020)
7.5 India Oncolytic Virus Cancer Immunotherapy Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia Oncolytic Virus Cancer Immunotherapy Revenue and Growth Rate (2015-2020)
8 South America Oncolytic Virus Cancer Immunotherapy Revenue by Countries
8.1 South America Oncolytic Virus Cancer Immunotherapy Revenue by Countries (2015-2020)
8.2 Brazil Oncolytic Virus Cancer Immunotherapy Revenue and Growth Rate (2015-2020)
8.3 Argentina Oncolytic Virus Cancer Immunotherapy Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue Oncolytic Virus Cancer Immunotherapy by Countries
9.1 Middle East & Africa Oncolytic Virus Cancer Immunotherapy Revenue by Countries (2015-2020)
9.2 Saudi Arabia Oncolytic Virus Cancer Immunotherapy Revenue and Growth Rate (2015-2020)
9.3 UAE Oncolytic Virus Cancer Immunotherapy Revenue and Growth Rate (2015-2020)
9.4 Egypt Oncolytic Virus Cancer Immunotherapy Revenue and Growth Rate (2015-2020)
9.5 South Africa Oncolytic Virus Cancer Immunotherapy Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global Oncolytic Virus Cancer Immunotherapy Revenue and Market Share by Type (2015-2020)
10.2 Global Oncolytic Virus Cancer Immunotherapy Market Forecast by Type (2019-2024)
10.3 Monoclonal Antibodies Revenue Growth Rate (2015-2025)
10.4 Checkpoint Inhibitors Revenue Growth Rate (2015-2025)
10.5 Oncoloytic Viral Therapies and Cancer Vaccines Revenue Growth Rate (2015-2025)
11 Global Oncolytic Virus Cancer Immunotherapy Market Segment by Application
11.1 Global Oncolytic Virus Cancer Immunotherapy Revenue Market Share by Application (2015-2020)
11.2 Oncolytic Virus Cancer Immunotherapy Market Forecast by Application (2019-2024)
11.3 Lung Cancer Revenue Growth (2015-2020)
11.4 Breast Cancer Revenue Growth (2015-2020)
11.5 Colorectal Cancer Revenue Growth (2015-2020)
11.6 Melanoma Revenue Growth (2015-2020)
11.7 Prostate Cancer Revenue Growth (2015-2020)
11.8 Head and neck Cancer Revenue Growth (2015-2020)
11.9 Ovarian Cancer Revenue Growth (2015-2020)
11.10 Pancreatic Cancer Revenue Growth (2015-2020)
11.11 Others Revenue Growth (2015-2020)
12 Global Oncolytic Virus Cancer Immunotherapy Market Size Forecast (2021-2025)
12.1 Global Oncolytic Virus Cancer Immunotherapy Market Size Forecast (2021-2025)
12.2 Global Oncolytic Virus Cancer Immunotherapy Market Forecast by Regions (2021-2025)
12.3 North America Oncolytic Virus Cancer Immunotherapy Revenue Market Forecast (2021-2025)
12.4 Europe Oncolytic Virus Cancer Immunotherapy Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific Oncolytic Virus Cancer Immunotherapy Revenue Market Forecast (2021-2025)
12.6 South America Oncolytic Virus Cancer Immunotherapy Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa Oncolytic Virus Cancer Immunotherapy Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US
List of Tables
Table 1. Global Oncolytic Virus Cancer Immunotherapy Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Oncolytic Virus Cancer Immunotherapy by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Oncolytic Virus Cancer Immunotherapy Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Global Market Oncolytic Virus Cancer Immunotherapy Revenue (Million USD) Comparison by Regions 2015-2025
Table 5. AstraZeneca Corporate Information, Location and Competitors
Table 6. AstraZeneca Oncolytic Virus Cancer Immunotherapy Major Business
Table 7. AstraZeneca Oncolytic Virus Cancer Immunotherapy Total Revenue (USD Million) (2017-2018)
Table 8. AstraZeneca SWOT Analysis
Table 9. AstraZeneca Oncolytic Virus Cancer Immunotherapy Product and Solutions
Table 10. AstraZeneca Oncolytic Virus Cancer Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 11. Biovex Corporate Information, Location and Competitors
Table 12. Biovex Oncolytic Virus Cancer Immunotherapy Major Business
Table 13. Biovex Oncolytic Virus Cancer Immunotherapy Total Revenue (USD Million) (2018-2019)
Table 14. Biovex SWOT Analysis
Table 15. Biovex Oncolytic Virus Cancer Immunotherapy Product and Solutions
Table 16. Biovex Oncolytic Virus Cancer Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 17. Bristol-Myers Squibb Corporate Information, Location and Competitors
Table 18. Bristol-Myers Squibb Oncolytic Virus Cancer Immunotherapy Major Business
Table 19. Bristol-Myers Squibb Oncolytic Virus Cancer Immunotherapy Total Revenue (USD Million) (2017-2018)
Table 20. Bristol-Myers Squibb SWOT Analysis
Table 21. Bristol-Myers Squibb Oncolytic Virus Cancer Immunotherapy Product and Solutions
Table 22. Bristol-Myers Squibb Oncolytic Virus Cancer Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 23. Amgen Corporate Information, Location and Competitors
Table 24. Amgen Oncolytic Virus Cancer Immunotherapy Major Business
Table 25. Amgen Oncolytic Virus Cancer Immunotherapy Total Revenue (USD Million) (2017-2018)
Table 26. Amgen SWOT Analysis
Table 27. Amgen Oncolytic Virus Cancer Immunotherapy Product and Solutions
Table 28. Amgen Oncolytic Virus Cancer Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 29. Pfizer Corporate Information, Location and Competitors
Table 30. Pfizer Oncolytic Virus Cancer Immunotherapy Major Business
Table 31. Pfizer Oncolytic Virus Cancer Immunotherapy Total Revenue (USD Million) (2017-2018)
Table 32. Pfizer SWOT Analysis
Table 33. Pfizer Oncolytic Virus Cancer Immunotherapy Product and Solutions
Table 34. Pfizer Oncolytic Virus Cancer Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 35. F Hoffman-La Roche Corporate Information, Location and Competitors
Table 36. F Hoffman-La Roche Oncolytic Virus Cancer Immunotherapy Major Business
Table 37. F Hoffman-La Roche Oncolytic Virus Cancer Immunotherapy Total Revenue (USD Million) (2017-2018)
Table 38. F Hoffman-La Roche SWOT Analysis
Table 39. F Hoffman-La Roche Oncolytic Virus Cancer Immunotherapy Product and Solutions
Table 40. F Hoffman-La Roche Oncolytic Virus Cancer Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 41. Crusade Laboratories Corporate Information, Location and Competitors
Table 42. Crusade Laboratories Oncolytic Virus Cancer Immunotherapy Major Business
Table 43. Crusade Laboratories Oncolytic Virus Cancer Immunotherapy Total Revenue (USD Million) (2017-2018)
Table 44. Crusade Laboratories SWOT Analysis
Table 45. Crusade Laboratories Oncolytic Virus Cancer Immunotherapy Product and Solutions
Table 46. Crusade Laboratories Oncolytic Virus Cancer Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 47. Merck & Co., Inc. Corporate Information, Location and Competitors
Table 48. Merck & Co., Inc. Oncolytic Virus Cancer Immunotherapy Major Business
Table 49. Merck & Co., Inc. Oncolytic Virus Cancer Immunotherapy Total Revenue (USD Million) (2017-2018)
Table 50. Merck & Co., Inc. SWOT Analysis
Table 51. Merck & Co., Inc. Oncolytic Virus Cancer Immunotherapy Product and Solutions
Table 52. Merck & Co., Inc. Oncolytic Virus Cancer Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 53. Novartis AG Corporate Information, Location and Competitors
Table 54. Novartis AG Oncolytic Virus Cancer Immunotherapy Major Business
Table 55. Novartis AG Oncolytic Virus Cancer Immunotherapy Total Revenue (USD Million) (2017-2018)
Table 56. Novartis AG SWOT Analysis
Table 57. Novartis AG Oncolytic Virus Cancer Immunotherapy Product and Solutions
Table 58. Novartis AG Oncolytic Virus Cancer Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 59. Cell Genesys Corporate Information, Location and Competitors
Table 60. Cell Genesys Oncolytic Virus Cancer Immunotherapy Major Business
Table 61. Cell Genesys Oncolytic Virus Cancer Immunotherapy Total Revenue (USD Million) (2017-2018)
Table 62. Cell Genesys SWOT Analysis
Table 63. Cell Genesys Oncolytic Virus Cancer Immunotherapy Product and Solutions
Table 64. Cell Genesys Oncolytic Virus Cancer Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 65. Genelux Corporation Corporate Information, Location and Competitors
Table 66. Genelux Corporation Oncolytic Virus Cancer Immunotherapy Major Business
Table 67. Genelux Corporation Oncolytic Virus Cancer Immunotherapy Total Revenue (USD Million) (2017-2018)
Table 68. Genelux Corporation SWOT Analysis
Table 69. Genelux Corporation Oncolytic Virus Cancer Immunotherapy Product and Solutions
Table 70. Genelux Corporation Oncolytic Virus Cancer Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 71. Lokon Pharma Corporate Information, Location and Competitors
Table 72. Lokon Pharma Oncolytic Virus Cancer Immunotherapy Major Business
Table 73. Lokon Pharma Oncolytic Virus Cancer Immunotherapy Total Revenue (USD Million) (2017-2018)
Table 74. Lokon Pharma SWOT Analysis
Table 75. Lokon Pharma Oncolytic Virus Cancer Immunotherapy Product and Solutions
Table 76. Lokon Pharma Oncolytic Virus Cancer Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 77. MultiVir Corporate Information, Location and Competitors
Table 78. MultiVir Oncolytic Virus Cancer Immunotherapy Major Business
Table 79. MultiVir Oncolytic Virus Cancer Immunotherapy Total Revenue (USD Million) (2017-2018)
Table 80. MultiVir SWOT Analysis
Table 81. MultiVir Oncolytic Virus Cancer Immunotherapy Product and Solutions
Table 82. MultiVir Oncolytic Virus Cancer Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 83. Global Oncolytic Virus Cancer Immunotherapy Revenue (Million USD) by Players (2015-2020)
Table 84. Global Oncolytic Virus Cancer Immunotherapy Revenue Share by Players (2015-2020)
Table 85. Global Oncolytic Virus Cancer Immunotherapy Revenue (Million USD) by Regions (2015-2020)
Table 86. Global Oncolytic Virus Cancer Immunotherapy Revenue Market Share by Regions (2015-2020)
Table 87. North America Oncolytic Virus Cancer Immunotherapy Revenue by Countries (2015-2020)
Table 88. North America Oncolytic Virus Cancer Immunotherapy Revenue Market Share by Countries (2015-2020)
Table 89. Europe Oncolytic Virus Cancer Immunotherapy Revenue (Million USD) by Countries (2015-2020)
Table 90. Asia-Pacific Oncolytic Virus Cancer Immunotherapy Revenue (Million USD) by Countries (2015-2020)
Table 91. South America Oncolytic Virus Cancer Immunotherapy Revenue by Countries (2015-2020)
Table 92. South America Oncolytic Virus Cancer Immunotherapy Revenue Market Share by Countries (2015-2020)
Table 93. Middle East and Africa Oncolytic Virus Cancer Immunotherapy Revenue (Million USD) by Countries (2015-2020)
Table 94. Middle East and Africa Oncolytic Virus Cancer Immunotherapy Revenue Market Share by Countries (2015-2020)
Table 95. Global Oncolytic Virus Cancer Immunotherapy Revenue (Million USD) by Type (2015-2020)
Table 96. Global Oncolytic Virus Cancer Immunotherapy Revenue Share by Type (2015-2020)
Table 97. Global Oncolytic Virus Cancer Immunotherapy Revenue Forecast by Type (2021-2025)
Table 98. Global Oncolytic Virus Cancer Immunotherapy Revenue by Application (2015-2020)
Table 99. Global Oncolytic Virus Cancer Immunotherapy Revenue Share by Application (2015-2020)
Table 100. Global Oncolytic Virus Cancer Immunotherapy Revenue Forecast by Application (2021-2025)
Table 101. Global Oncolytic Virus Cancer Immunotherapy Revenue (Million USD) Forecast by Regions (2021-2025)
List of Figures
Figure 1. Oncolytic Virus Cancer Immunotherapy Picture
Figure 2. Global Oncolytic Virus Cancer Immunotherapy Revenue Market Share by Type in 2019
Figure 3. Monoclonal Antibodies Picture
Figure 4. Checkpoint Inhibitors Picture
Figure 5. Oncoloytic Viral Therapies and Cancer Vaccines Picture
Figure 6. Oncolytic Virus Cancer Immunotherapy Revenue Market Share by Application in 2019
Figure 7. Lung Cancer Picture
Figure 8. Breast Cancer Picture
Figure 9. Colorectal Cancer Picture
Figure 10. Melanoma Picture
Figure 11. Prostate Cancer Picture
Figure 12. Head and neck Cancer Picture
Figure 13. Ovarian Cancer Picture
Figure 14. Pancreatic Cancer Picture
Figure 15. Others Picture
Figure 16. Global Oncolytic Virus Cancer Immunotherapy Revenue (USD Million) and Growth Rate (2015-2025)
Figure 17. North America Oncolytic Virus Cancer Immunotherapy Revenue (Million USD) and Growth Rate (2015-2025)
Figure 18. Europe Oncolytic Virus Cancer Immunotherapy Revenue (Million USD) and Growth Rate (2015-2025)
Figure 19. Asia-Pacific Oncolytic Virus Cancer Immunotherapy Revenue (Million USD) and Growth Rate (2015-2025)
Figure 20. South America Oncolytic Virus Cancer Immunotherapy Revenue (Million USD) and Growth Rate (2015-2025)
Figure 21. Middle East and Africa Oncolytic Virus Cancer Immunotherapy Revenue (Million USD) and Growth Rate (2015-2025)
Figure 22. Global Oncolytic Virus Cancer Immunotherapy Revenue (Million USD) and Growth Rate (2015-2025)
Figure 23. Global Oncolytic Virus Cancer Immunotherapy Revenue Share by Players in 2019
Figure 24. Global Top 5 Players Oncolytic Virus Cancer Immunotherapy Revenue Market Share in 2019
Figure 25. Global Top 10 Players Oncolytic Virus Cancer Immunotherapy Revenue Market Share in 2019
Figure 26. Key Players Market Share Trend
Figure 27. Global Oncolytic Virus Cancer Immunotherapy Revenue (Million USD) and Growth Rate (%) (2015-2020)
Figure 28. Global Oncolytic Virus Cancer Immunotherapy Revenue Market Share by Regions (2015-2020)
Figure 29. Global Oncolytic Virus Cancer Immunotherapy Revenue Market Share by Regions in 2018
Figure 30. North America Oncolytic Virus Cancer Immunotherapy Revenue and Growth Rate (2015-2020)
Figure 31. Europe Oncolytic Virus Cancer Immunotherapy Revenue and Growth Rate (2015-2020)
Figure 32. Asia-Pacific Oncolytic Virus Cancer Immunotherapy Revenue and Growth Rate (2015-2020)
Figure 33. South America Oncolytic Virus Cancer Immunotherapy Revenue and Growth Rate (2015-2020)
Figure 34. Middle East and Africa Oncolytic Virus Cancer Immunotherapy Revenue and Growth Rate (2015-2020)
Figure 35. North America Oncolytic Virus Cancer Immunotherapy Revenue Market Share by Countries (2015-2020)
Figure 36. North America Oncolytic Virus Cancer Immunotherapy Revenue Market Share by Countries in 2019
Figure 37. USA Oncolytic Virus Cancer Immunotherapy Revenue and Growth Rate (2015-2020)
Figure 38. Canada Oncolytic Virus Cancer Immunotherapy Revenue and Growth Rate (2015-2020)
Figure 39. Mexico Oncolytic Virus Cancer Immunotherapy Revenue and Growth Rate (2015-2020)
Figure 40. Europe Oncolytic Virus Cancer Immunotherapy Revenue Market Share by Countries (2015-2020)
Figure 41. Europe Oncolytic Virus Cancer Immunotherapy Revenue Market Share by Countries in 2019
Figure 42. Germany Oncolytic Virus Cancer Immunotherapy Revenue and Growth Rate (2015-2020)
Figure 43. UK Oncolytic Virus Cancer Immunotherapy Revenue and Growth Rate (2015-2020)
Figure 44. France Oncolytic Virus Cancer Immunotherapy Revenue and Growth Rate (2015-2020)
Figure 45. Russia Oncolytic Virus Cancer Immunotherapy Revenue and Growth Rate (2015-2020)
Figure 46. Italy Oncolytic Virus Cancer Immunotherapy Revenue and Growth Rate (2015-2020)
Figure 47. Asia-Pacific Oncolytic Virus Cancer Immunotherapy Revenue Market Share by Countries (2015-2020)
Figure 48. Asia-Pacific Oncolytic Virus Cancer Immunotherapy Revenue Market Share by Countries in 2019
Figure 49. China Oncolytic Virus Cancer Immunotherapy Revenue and Growth Rate (2015-2020)
Figure 50. Japan Oncolytic Virus Cancer Immunotherapy Revenue and Growth Rate (2015-2020)
Figure 51. Korea Oncolytic Virus Cancer Immunotherapy Revenue and Growth Rate (2015-2020)
Figure 52. India Oncolytic Virus Cancer Immunotherapy Revenue and Growth Rate (2015-2020)
Figure 53. Southeast Asia Oncolytic Virus Cancer Immunotherapy Revenue and Growth Rate (2015-2020)
Figure 54. South America Oncolytic Virus Cancer Immunotherapy Revenue Market Share by Countries (2015-2020)
Figure 55. South America Oncolytic Virus Cancer Immunotherapy Revenue Market Share by Countries in 2019
Figure 56. Brazil Oncolytic Virus Cancer Immunotherapy Revenue and Growth Rate (2015-2020)
Figure 57. Argentina Oncolytic Virus Cancer Immunotherapy Revenue and Growth Rate (2015-2020)
Figure 58. Middle East and Africa Oncolytic Virus Cancer Immunotherapy Revenue Market Share by Countries (2015-2020)
Figure 59. Middle East and Africa Oncolytic Virus Cancer Immunotherapy Revenue Market Share by Countries in 2019
Figure 60. Saudi Arabia Oncolytic Virus Cancer Immunotherapy Revenue and Growth Rate (2015-2020)
Figure 61. UAE Oncolytic Virus Cancer Immunotherapy Revenue and Growth Rate (2015-2020)
Figure 62. Egypt Oncolytic Virus Cancer Immunotherapy Revenue and Growth Rate (2015-2020)
Figure 63. South Africa Oncolytic Virus Cancer Immunotherapy Revenue and Growth Rate (2015-2020)
Figure 64. Global Oncolytic Virus Cancer Immunotherapy Revenue Share by Type (2015-2020)
Figure 65. Global Oncolytic Virus Cancer Immunotherapy Revenue Share by Type in 2019
Figure 66. Global Oncolytic Virus Cancer Immunotherapy Market Share Forecast by Type (2021-2025)
Figure 67. Global Monoclonal Antibodies Revenue Growth Rate (2015-2020)
Figure 68. Global Checkpoint Inhibitors Revenue Growth Rate (2015-2020)
Figure 69. Global Oncoloytic Viral Therapies and Cancer Vaccines Revenue Growth Rate (2015-2020)
Figure 70. Global Oncolytic Virus Cancer Immunotherapy Revenue Share by Application (2015-2020)
Figure 71. Global Oncolytic Virus Cancer Immunotherapy Revenue Share by Application in 2019
Figure 72. Global Oncolytic Virus Cancer Immunotherapy Market Share Forecast by Application (2021-2025)
Figure 73. Global Lung Cancer Revenue Growth Rate (2015-2020)
Figure 74. Global Breast Cancer Revenue Growth Rate (2015-2020)
Figure 75. Global Colorectal Cancer Revenue Growth Rate (2015-2020)
Figure 76. Global Melanoma Revenue Growth Rate (2015-2020)
Figure 77. Global Prostate Cancer Revenue Growth Rate (2015-2020)
Figure 78. Global Head and neck Cancer Revenue Growth Rate (2015-2020)
Figure 79. Global Ovarian Cancer Revenue Growth Rate (2015-2020)
Figure 80. Global Pancreatic Cancer Revenue Growth Rate (2015-2020)
Figure 81. Global Others Revenue Growth Rate (2015-2020)
Figure 82. Global Oncolytic Virus Cancer Immunotherapy Revenue (Million USD) and Growth Rate Forecast (2021-2025)
Figure 83. Global Oncolytic Virus Cancer Immunotherapy Revenue (Million USD) Forecast by Regions (2021-2025)
Figure 84. Global Oncolytic Virus Cancer Immunotherapy Revenue Market Share Forecast by Regions (2021-2025)
Figure 85. North America Oncolytic Virus Cancer Immunotherapy Revenue Market Forecast (2021-2025)
Figure 86. Europe Oncolytic Virus Cancer Immunotherapy Revenue Market Forecast (2021-2025)
Figure 87. Asia-Pacific Oncolytic Virus Cancer Immunotherapy Revenue Market Forecast (2021-2025)
Figure 88. South America Oncolytic Virus Cancer Immunotherapy Revenue Market Forecast (2021-2025)
Figure 89. Middle East and Africa Oncolytic Virus Cancer Immunotherapy Revenue Market Forecast (2021-2025)
Figure 90. Sales Channel: Direct Channel vs Indirect Channel